CAJ | 학술논문

呼吸困难是慢性阻塞性肺疾病(chronic obstructive pulmonary disease,COPD)的首要症状,也是COPD患者最痛苦的症状.COPD诊断、处理和预防全球策略2011年报告推荐采用修订版呼吸困难分级(the modified Medical Research Council Dyspnea Scale,mMRC)评估COPD患者的呼吸困难,对mMRC达到和(或)超过2分的患者积极进行药物干预,以缓解呼吸困难.指南建议转化到临床实践的过程中,医师需要认识COPD呼吸困难的发生机制；理解呼吸困难测量工具的测定原理,包括信度、效度、对呼吸困难变化的敏感度；各种新老药物缓解呼吸困难的疗效.这篇文章从呼吸困难发生机制、呼吸困难测量、呼吸困难治疗三方面,综述COPD呼吸困难的最新进展.
호흡곤난시만성조새성폐질병(chronic obstructive pulmonary disease,COPD)적수요증상,야시COPD환자최통고적증상.COPD진단、처리화예방전구책략2011년보고추천채용수정판호흡곤난분급(the modified Medical Research Council Dyspnea Scale,mMRC)평고COPD환자적호흡곤난,대mMRC체도화(혹)초과2분적환자적겁진행약물간예,이완해호흡곤난.지남건의전화도림상실천적과정중,의사수요인식COPD호흡곤난적발생궤제；리해호흡곤난측량공구적측정원리,포괄신도、효도、대호흡곤난변화적민감도；각충신로약물완해호흡곤난적료효.저편문장종호흡곤난발생궤제、호흡곤난측량、호흡곤난치료삼방면,종술COPD호흡곤난적최신진전.
Dyspnea is a first symptom and the most disabling symptom in majority of patients with chronic obstructive pulmonary disease (COPD),GOLD 201l report recommends the use of the Modified British Medical Research Council (mMRC) to assess dyspnea,and the appropriate pharmacologic therapy to relieve dyspnea in all patients with mMRC scored 2 or more,However,in translation of the guideline recommendations into patient care,chest physicians need to understand the mechanisms contributing to breathlessness in patients with COPD,the development and testing (validity,reliability,and responsiveness) of different instruments used to measure dyspnea in clinical settings,and efficacy and effectiveness of both old and new pharmacologic options for the relief of dyspnea,This review fulfills these purposes and provides the updated information on mechanism,measurement,and pharmacologic management of dyspnea in patients with COPD.